PROFIL PASIEN DAN PENGOBATAN OAT PADA PASIEN MDR-TB DI RSUD DR. SOEKARDJO TASIKMALAYA: PROFIL PASIEN DAN PENGOBATAN OAT PADA PASIEN MDR-TB DI RSUD DR. SOEKARDJO TASIKMALAYA

Citra Salasanti; Ilham Alifiar; Wafiq Nur’azizah; Dani Farid Abdullah

doi:10.29313/jiff.v8i1.4490

Authors

Citra Salasanti Universits Bakti Tunas Husada
Ilham Alifiar Program Studi Farmasi, Fakultas Farmasi, Universitas Bakti Tunas Husada Tasikmalaya, Jawa Barat, Indonesia
Wafiq Nur’azizah Program Studi Farmasi, Fakultas Farmasi, Universitas Bakti Tunas Husada Tasikmalaya, Jawa Barat, Indonesia
Dani Farid Abdullah Poli TB MDR RSUD dr. Soekardjo Tasikmalaya, Jawa Barat, Indonesia

DOI:

https://doi.org/10.29313/jiff.v8i1.4490

Keywords:

Effectiveness, MDR-TB, Treatment Patterns

Abstract

Indonesia is ranked 5th in the world for the most MDR-TB cases. The treatment for MDR-TB differs from regular TB cases, as it involves using second-line anti-TB drugs (OAT). This study aims to determine the patient profile, treatment patterns, and effectiveness of OAT in MDR-TB patients at RSUD Dr. Soekardjo Tasikmalaya. The research was conducted using a descriptive observational method with a cross-sectional design, collecting data retrospectively from the medical records of MDR-TB patients from January to December 2023. The sample size in this study was 32 patients.The results showed that the majority of MDR-TB patients were in the age range of 18-44 years (71.87%), 56.25% were male, 28.16% were unemployed and housewives, and 62.50% had new patients. Among the 32 patients, 3 underwent short-term therapy, while 29 underwent long-term therapy. The effectiveness of the treatment was evaluated through BTA culture, conducted monthly. Based on BTA conversion results, 25 out of 32 patients showed negative results from the first month of treatment.

References

Anisah, A., Sumekar, D. W., & Budiarti, E. (2021). Hubungan Demografi dan Komorbid dengan Kejadian Tuberkulosis Resisten Obat (TB RO). Jurnal Ilmiah Kesehatan Sandi Husada, 10(2), 568–574. https://doi.org/10.35816/jiskh.v10i2.655

Ariyanto, D., Achsan, M., Sofro, U., Dwidayani, M., Studi, P., Keperawatan, I., & Keperawatan, D. (2020). Tingkat Depresi Pasien TB-MDR. Jurnal Ilmu Keperawatan Jiwa, 3(3), 277–290.

Auliandari, R. A., Sutiningsih, D., Laksono, B., & Sakundarno, M. (2023). Tinjauan Lliteratur : Faktor Klinis yang Berhubungan dengan Kejadian Resistensi Obat Pada Pasien Tuberkulosis. Jurnal Kesehatan Tadulako, 9(3), 331–339.

Aviana, F., Jati, S. P., & Budiyanti, R. T. (2021). Systematic Review Pelaksanaan Programmatic Management of Drug-Resistant Tuberculosis Pada Pasien Tuberkulosis Resistan Obat. Jurnal Kesehatan Masyarakat (Undip), 9(2), 215–222. https://doi.org/10.14710/jkm.v9i2.28719

Baya, B., Achenbach, C. J., Kone, B., Toloba, Y., Dabitao, D. K., Diarra, B., Goita, D., Diabaté, S., Maiga, M., Soumare, D., Ouattara, K., Kanoute, T., Berthe, G., Kamia, Y. M., Sarro, Y. dit S., Sanogo, M., Togo, A. C. G., Dembele, B. P. P., Coulibaly, N., … Diallo, S. (2019). Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. International Journal of Infectious Diseases, 81, 149–155. https://doi.org/10.1016/j.ijid.2019.02.004

Diantara, L. B., Hasyim, H., Septeria, I. P., Sari, D. T., Wahyuni, G. T., & Anliyanita, R. (2022). TUBERKULOSIS MASALAH KESEHATAN DUNIA: TINJAUAN LITERATUR. Jurnal ’Aisyiyah Medika, 7(2), 78–88.

Kemenkes RI. (2016). Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 Tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019. Kementerian Kesehatan RI.

Kemenkes RI. (2020). Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia. Kementerian Kesehatan RI.

Kemenkes RI. (2023). Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Kementerian Kesehatan RI.

Nurjannah, A., Yulisa Rahmalia, F., Retno Paramesti, H., Asra Laily, L., Kharisma Pradani, F. P., Ainun Nisa, A., & Nugroho, E. (2022). Determinan Sosial Tuberculosis di Indonesia. Jurnal Penelitian Dan Pengembangan Kesehatan Masyarakat Indonesia, 3(1), 65–76. https://journal.unnes.ac.id/sju/index.php/jppkmi

Rachmawati, R. L., Widjanarko, B., & Sriatmi, A. (2023). Penemuan dan Penanganan Multidrug-Resistant Tuberculosis (MDR-TB) di Fasyankes Kabupaten Pati. Jurnal Kesehatan Masyarakat, 11(2), 222–239.

Rizal, V. P., Rustam, E., & Anggrainy, F. (2021). Karakteristik Pasien Multidrug Resistant Tuberculosis yang Dirawat di Bangsal Paru RSUP Dr. M. Djamil Padang Periode 2018 – 2020. Jurnal Farmasi Higea, 13(2), 143. https://doi.org/10.52689/higea.v13i2.388

Rupani, M. P., Dave, J. D., Parmar, V. B., Singh, M. P., & Parikh, K. D. (2020). Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India. National Medical Journal of India, 33(1), 10–14. https://doi.org/10.4103/0970-258X.308234

Sari, E., Zakiah, N., Santoso, P., & Barliana, M. I. (2020). Efektivitas Terapi Bedaquilin Dan Delamanid Pada Pengobatan Multidrug-Resistant Tuberculosis (MDR-TB). Jurnal Sains Dan Teknologi Farmasi Indonesia, 9(1). https://doi.org/10.58327/jstfi.v9i1.138

Sari, G. A. L. P., & Herawati, F. (2023). Efektivitas dan Keamanan Terapi dengan Rejimen yang Mengandung Linezolid dalam pengobatan multidrug-resistant tuberculosis ( MDR-TB ): Kajian Sistematik. Pharmaceutical Journal of Indonesia, 8(2), 179–186.

Septyani, N. D. P., Lestari, F., & Suwendar. (2020). Efektivitas Penggunaan Obat Antituberkulosis ( Oat ) Lini Kedua Pada Pasien Multidrug Resistant Tuberculosis ( Mdr-Tb ) di Indonesia. Universitas Islam Bandung, Indonesia, 6(2), 1–8.

Sutrisna, M., & Elsi Rahmadani. (2022). Hubungan Usia dan Jenis Kelamin dengan TB MDR. Sehat Rakyat: Jurnal Kesehatan Masyarakat, 1(4), 370–376. https://doi.org/10.54259/sehatrakyat.v1i4.1168

WHO. (2022). Anual Report of Tubervulosis. In Global TB Report of WHO (pp. 1–51).

World Health Organization, (WHO). (2022). WHO consolidated guidelines on tuberculosis. In WHO Press.

Yobeanto, N., & Setiawan, T. L. (2022). Pola Resistensi Kuman Mycrobacterium Tuberculosis Terhadap Obat Antituberculosis Lini Pertama. Health Sains, 3(5), 654–662.